Advanced Kidney Cancer Treatment: New Combo Therapy Doubles Survival Rates
Groundbreaking Cancer Treatment
In a recent clinical trial, researchers at Roswell Park Comprehensive Cancer Center have made significant strides in the treatment of advanced kidney cancer. By combining two existing drugs, pazopanib (Votrient) and bevacizumab (Avastin), they have succeeded in doubling patient survival rates.
Trial Findings
This trial included 51 patients, revealing that the combination not only led to improvements in health outcomes but also increased the average progression-free survival time from just over 11 months to more than 23 months.
- Pazopanib blocks VEGF signaling, crucial for cancer cell growth.
- This innovative treatment was administered in 10-week cycles.
What This Means for Patients
By using pazopanib first for 28 days, followed by bevacizumab, researchers aim to prevent resistance to treatment. This effective approach indicates a new potential standard in cancer treatment, fostering hope for patients battling advanced kidney cancer.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.